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Breast cancer affects one in nine women in their lifetime (Kelsey,
1979). In more than 90% of cases, the disease arises sporadically,
with no previous associated family history. Several genes (e.g.
BRCA1, BRCA2) have been shown to have a role in susceptibility
to inherited breast cancer. Because of this association, such genes
have been extensively investigated in sporadic breast tumours
(reviewed in Smith and Ponder, 1993; Stratton, 1996); however,
the genetic events occurring in the majority of these tumours still
remain to be identified. Additional candidate genes for involve-
ment in sporadic breast disease are those implicated in cancer
syndromes associated with an increased risk of breast cancer. One
such syndrome is Cowden disease (CD), or multiple hamartoma
syndrome, an autosomal dominantly inherited cancer syndrome
characterized by oral and cutaneous lesions and an increased risk
of follicular thyroid tumours and breast carcinomas (Brownstein 
et al, 1978; Starink et al, 1986). The incidence of breast cancer
among women with CD is estimated to be 30–50% (Starink et al,
1986).
The gene for CD was initially mapped by linkage analysis to
10q22–23, within a 5-cM interval flanked by D10S215 and
D10S564 (Nelen et al, 1996). Loss of heterozygosity (LOH) of this
interval was also observed in some tumours from CD patients
(Marsh et al, 1997), suggesting the CD gene was a tumour
suppressor. In addition to those tumours associated with CD, other
human cancers have been shown to have losses of this region of
chromosome 10 (Moschonas et al, 1996). A candidate tumour-
suppressor gene for glioblastoma multiforme has been mapped to
10q24–qter (Karlbom et al, 1993; Pershouse et al, 1993; Rasheed
et al, 1995; Albarosa et al, 1996), whereas a region in 10q23–q26
is frequently deleted in endometrial cancers (Simon et al, 1990;
Peiffer et al, 1995). Common deleted regions have also been noted
in renal cell carcinoma at 10q21–q22 (Morita et al, 1991), at
10q22–qter in malignant melanoma (Parmiter et al, 1988; Herbst
et al, 1994), at 10q22.3–q23.1 in muscle-invasive bladder cancers
(Kagan et al, 1998) and at 10q23–q24 in prostate cancer (Gray et
al, 1996; Ittmann, 1996; Trybus et al, 1996; Feilotter et al, 1998).
Germline mutations of the PTEN/MMAC1 tumour-suppressor
gene (Li et al, 1997; Steck et al, 1997), which lies within the
10q22–23 critical interval, have been identified in the majority of
CD families (Liaw et al, 1997; Lynch et al, 1997; Nelen et al,
1997; Tsou et al, 1997; Marsh et al, 1998a). However, mutations
are rare or absent in breast cancer families without other typical
CD stigmata (Tsou et al, 1997; Chen et al, 1998; FitzGerald et al,
1998). Somatic mutations of this gene have been found at varying
frequencies in some of the tumour types described above. PTEN
mutations are frequent in endometrial carcinoma (Kong et al,
1997; Risinger et al, 1997; Tashiro et al, 1997), malignant
melanoma (Guldberg et al, 1997), high-grade gliomas (Rasheed 
et al, 1997; Wang et al, 1997; Bostrom et al, 1998) and metastatic
prostate cancer (Cairns et al, 1997; Suzuki et al, 1998). However,
mutations are rare in unselected prostate carcinoma (Feilotter et al,
1998), meningioma (Bostrom et al, 1998), low-grade gliomas
(Rasheed et al, 1997) and unselected breast carcinoma (Rhei et al,
1997). Thus, it appears that the PTEN tumour suppressor may play
a role in a subset of the advanced human cancers noted above, but
not in all of these neoplasms. It is still not clear whether other
tumour-suppressor genes which contribute to multiple tumour
types lie close to PTEN on 10q23. In this study, we have investi-
gated LOH in the 10q22–23 region in a series of primary breast
carcinomas. We have further analysed those tumours with LOH in
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this critical region for mutations of the PTEN gene to clarify the
role of PTEN, or closely linked tumour-suppressor genes, in this
disease.
MATERIALS AND METHODS
Samples
We used a panel of 70 unselected sporadic primary breast cancers
and matched normal tissue from two series for LOH on chromo-
some 10q, with particular attention to a 10-cM interval at 10q23
which spans the PTEN locus. Sixty-eight of the 70 samples were
infiltrating ductal carcinomas, whereas the remaining two were
infiltrating lobular carcinomas. The selected cases did not have 
a history of familial breast cancer or other cancer-related
syndromes. Samples collected at the Institut Bergonié (cases 3–36)
were isolated from fresh surgical material and snap-frozen in
liquid nitrogen before DNA extraction. Peripheral blood leuco-
cytes were obtained as a source of matched constitutional DNA.
Genomic DNA purification from blood and snap-frozen tissue
samples was according to published protocols (Dorion-Bonnet 
et al, 1995). DNA from samples collected at Kingston General
Hospital (cases 37–72) was extracted from formalin-fixed
paraffin-embedded archival material according to published proto-
cols (Wright and Manos, 1990). Before each DNA extraction,
tumour tissues were microdissected from contaminating normal
cells using a haematoxylin phloxine saffron-stained section for
reference. Control blood DNAs from a panel of 60 unrelated indi-
viduals were extracted using established protocols and have been
previously described (Feilotter et al, 1998).
LOH analyses
Seven microsatellite markers, known to map to the 10q23 interval,
were analysed. The order of these markers from centromere 
to telomere was D10S579, D10S215, D10S1765, D10S541,
D10S1735,  D10S1739,  D10S564 based on published maps
(Gyapay et al, 1994; Chumakov et al, 1995; Moschonas et al,
1996; Nelen et al, 1996; Gray et al, 1997; Marsh et al, 1997) and
data from the Center for Genome Research at the Whitehead
Institute for Biomedical Science (www-genome.wi.mit.edu).
Primer sequences for markers were obtained from the Genome
Data Base. Polymerase chain reactions (PCR) were carried out
according to published protocols using either fluorescently or
radiolabelled primers. For fluorescent products, allele loss was
scored when the ratio of peak heights of the tumour to the leuco-
cyte alleles, as determined by Genescan 672 software (Applied
Biosystems), exceeded 1.6 (Figure 1). This cut-off value repre-
sents a conservative scoring of allele loss, and is consistent with
that used in other studies of LOH (Gray et al, 1996; Trybus et al,
1996; Marsh et al, 1997). Samples with a ratio of peak heights
between 1.5 and 1.6 were considered ambiguous and were not
scored. For radiolabelled products (samples 37–72), allele loss
was scored by eye by two independent observers.
Single-strand conformation polymorphism (SSCP)
analysis
SSCP analysis of PTEN was performed using previously described
PCR conditions and intronic primers flanking each of the gene’s
nine exons (Feilotter et al, 1998). Aliquots of the labelled PCR
products were electrophoresed on non-denaturing acrylamide/
glycerol gels at 14°C for 16 h using a variety of polyacrylamide and
glycerol concentrations, ranging from 6% to 8% acrylamide and
from 0% to 10% glycerol. Gels were dried and exposed to film.
Denaturing gradient gel electrophoresis (DGGE)
analysis
DGGE was performed according to the methods described by
Stoppa-Lyonnet et al (1997). DGGE electrophoretic conditions
(optimized using Meltmap and SQHTX programs) and primer
sequences have been previously described (Laugé et al, 1998).
Sequencing analysis
Electrophoretic variants predicted by SSCP or DGGE were
confirmed by direct sequencing. PCR products were amplified
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Figure 1 Loss of heterozygosity analysis in tumour 22 for four informative markers. For each marker, the alleles present in normal (top) and tumour (bottom)
tissue are shown, with the ratio of normal/tumour allele peak heights given above. Ratios equal to or greater than 1.6 were scored as allele loss. A ratio of less
than 1.5 was scored as no loss. Thus, the figure depicts allele loss at D10S1765, D10S541 and D10S1735 and no loss at D10S215. The arrows indicate the
deleted alleles in the tumour samples720 HE Feilotter et al
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essentially as described above (Feilotter et al, 1998; Longy et al,
1998) except without the addition of isotope. Products were puri-
fied using the Wizard PCR Preps DNA purification system
(Promega) and sequenced using the Thermosequenase Sequencing
Kit (Amersham-Life Science) or the ABI Prism Dye Terminator
Sequencing Ready Reaction Kit (Perkin Elmer) according to the
manufacturer’s instructions.
RESULTS
Of the seventy pairs of matched breast carcinoma and germline
genomic DNAs examined, all were informative (heterozygous)
for at least one of the markers analysed. In total, 27 tumours (39%)
showed LOH at one or more marker loci. Twelve of these (71, 66,
10, 46, 58, 4, 56, 53, 27, 50, 55 and 65) exhibited allele loss for all
informative markers over the entire 10-cM region examined
(Figure 2). Thus, LOH in these tumours spanned extensive regions
of 10q and was not useful for further defining the critical deleted
interval or intervals. In the remaining 15 cases, LOH was detected
at only a subset of the informative loci within the 10q23 region.
The most frequent allele loss was at D10S1765, although loss
was common between D10S215 and D10S541. Thirteen out of the
15 tumours which showed loss at only a subset of loci had LOH
within this interval (59, 21, 40, 41, 6, 13, 14, 5, 52, 22, 11, 17 and
12) (Figure 2). This commonly deleted interval spans the PTEN
locus.
In addition to the interval described above, a distinct non-
overlapping region of allelic loss was seen in two samples (Figure
2). Tumours 68 and 39 showed allele loss only for markers telo-
meric of D10S541. Further, tumour 68 showed LOH at the 
more distal locus D10S574 (data not shown), suggesting that the
deleted interval spanned markers well telomeric of D10S564
(Figure 2).
PTEN mutation analyses
To investigate whether PTEN was the target of allele loss in
tumours where LOH was detected, we examined all nine exons of
the PTEN gene in each of the 27 tumours which showed allele loss
at 10q23 loci. For each tumour sample and control, PTEN exons
were amplified using intronic primers. PCR products with altered
mobility (SSCP) or denaturation profiles (DGGE), suggesting the
presence of mutations, were directly sequenced. SSCP and DGGE
variants were detected with PCR products corresponding to exons
2, 4 and 6. Sequencing of these variants confirmed that these prod-
ucts represented previously reported polymorphic alleles present
in the normal population (Rhei et al, 1997; Feilotter et al, 1998).
We did not detect mutations of the PTEN gene in any of the 27
breast carcinomas examined in this study. We conclude that muta-
tions of PTEN are not common in breast cancer.
DISCUSSION
The PTEN/MMAC1 gene lies between D10S1765 and D10S541
(Gray et al, 1996) within the major region of loss detected in this
study. The gene encodes a molecule with homology to two
cytoskeletal proteins, tensin and auxilin (Li et al, 1997; Steck et al,
1997). PTEN has demonstrated dual specificity phosphatase
activity (Li and Sun, 1997; Myers et al, 1997), which suggests a
role in both tyrosine and serine/threonine phosphatase-mediated
signal transduction.
Although frequent mutations of PTEN in a variety of tumour
types was predicted from early studies of tumour cell lines, this
has not been generally confirmed. Analyses of PTEN in primary
tumours have identified mutations in approximately one-third of
high-grade gliomas (Rasheed et al, 1997; Wang et al, 1997;
Bostrom et al, 1998) and about 50% of endometrial tumours
(Kong et al, 1997; Risinger et al, 1997; Tashiro et al, 1997).
However, mutations are common only in metastatic prostate
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Figure 2 Regions of allele loss for the 27 tumours showing LOH. Open circles = no LOH; filled circles = LOH, – = non-informative; na = not available. The
shading represents the maximum possible interval of loss for each tumour. Grade for each tumour is given as W, well differentiated; M, moderately
differentiated; MW, moderately/well differentiated; P, poorly differentiated, and S, special type, not graded (medullary carcinoma). Lymph node involvement is
indicated as number of axillary lymph nodes with metastatic cancer over the total number of nodes examinedPTEN in sporadic breast carcinoma 721
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carcinoma (Cairns et al, 1997; Feilotter et al, 1998; Suzuki et al,
1998) and malignant melanoma (Guldberg et al, 1997). In recent
studies, it has been shown that germline PTEN mutations are rare
or absent in cases of familial breast cancer or early onset breast
cancer without BRCA1 mutations (Tsou et al, 1997; Chen et al,
1998; FitzGerald et al, 1998). Li et al (1997) identified mutations
leading to truncation of the PTEN protein in 2 out of 20 (10%)
breast tumour cell lines examined. Studies in unselected series of
primary breast tumours have not identified high frequencies of
PTEN mutations in sporadic tumours (Rhei et al, 1997). In this
study, we examined a selected population of tumours already
shown to have LOH for the PTEN region, which might be
predicted to have a higher frequency of PTEN mutations.
Interestingly, our data are very similar to results from Rhei et al
(1997) who found only one PTEN mutation in 53 truly sporadic
tumours. The low frequency of PTEN mutations in breast cancer
cell lines and primary tumours, even in studies such as ours in
which samples were preselected for LOH in the PTEN region,
raises the possibility that another tumour-suppressor gene with a
role in sporadic breast cancers may lie within this interval on
10q23.
Genome-wide allelotyping studies of sporadic breast cancers
have not shown LOH above background levels on chromosome 10
(Sato et al, 1990; Devilee and Cornelisse, 1994; Bieché and
Lidereau, 1995; Fujii et al, 1996; Kerangueven et al, 1996).
However, these studies did not focus on the 10q23 region. In this
study, we saw LOH for one or more loci in 10q23 in 27 out of 70
sporadic breast carcinomas. In >90% of these cases, deletion
included the PTEN locus. Singh et al (1998) reported a similar
frequency of LOH (41%) for this interval in sporadic breast
tumours whereas Li et al (1997) saw LOH of PTEN in approxi-
mately 50% of primary tumours examined. Our data and those of
Singh et al (1998) suggest that the most common interval of loss
spans approximately 1 Mb of DNA which, although including the
PTEN locus, could also include one or more further genes. As yet,
additional loci within this interval, which might act as tumour-
suppressor genes in sporadic breast cancer, have not been identi-
fied. Clearly, the existence of such candidate genes, which are lost
in the samples studied here, remains to be determined.
Analysis of LOH in a variety of tumours has suggested that
multiple discrete regions of chromosome 10 loss may occur in a
single tumour or tumour type (Parmiter et al, 1988; Karlbom et al,
1993; Herbst et al, 1994; Peiffer et al, 1995; Albarosa et al, 1996;
Ittmann, 1996; Trybus et al, 1996; Zedenius et al, 1996; Marsh et
al 1998b). The precise physical localization of such deleted
regions with respect to one another and the number of tumour-
suppressor genes they represent has been difficult to determine, in
part because of the variety of markers used in the different studies.
Our identification of a second distinct deleted interval telomeric of
the D10S215/D10S541 interval is consistent with the suggestion
that other genes on 10q23, outside of the PTEN interval, may
contribute to some sporadic breast cancers. LOH analyses of a
larger population of sporadic breast tumours may help to clarify
this issue. The loss of multiple distinct regions on chromosome 10
may be analogous to the situation on chromosome 17 in sporadic
breast tumours, in which at least five distinct deleted regions have
been recognized (Nagai et al, 1994, 1995). In the case of chromo-
some 17, the pattern of LOH is significantly correlated with some
clinical parameters of the breast tumours (Bevilacqua et al, 1989;
Nagai et al, 1995; Midulla et al, 1996). Our data do not suggest any
association of chromosome 10 allele loss with tumour size, stage
or lymph node involvement, regardless of the deleted interval
(Figure 2), although our numbers are too small for subset analyses.
Singh et al (1998) has suggested a strong correlation of LOH in
10q23 with poorly differentiated cancers, although again the
numbers examined were small and PTEN mutation status was not
determined. Further study is required to confirm whether losses
can be correlated with these or other clinical parameters.
In summary, we have identified two discrete regions of LOH on
10q in sporadic breast carcinomas. Losses of the major region
identified in this study were found in 39% of the cases studied and
spanned the locus of the PTEN tumour suppressor. Mutations of
PTEN were not identified in any of these cases, suggesting other
candidate tumour-suppressor genes, important in breast cancer,
may lie within the same region. A tumour population with allele
losses in the 10q23 region, such as we have described here, will
provide a valuable tool for determining the relative contribution of
inactivation of the PTEN gene, or a neighbouring tumour-
suppressor gene, to breast tumorigenesis.
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